(Bloomberg) -- Drug price increases hurt patients and disrupt the supply of medicine in the U.S., experts told a Senate panel that’s investigating the industry.
While companies should be rewarded for developing new drugs, the system “never anticipated companies acquiring off- patent drugs and then jacking up their prices to enormous heights,” Senator Susan Collins, a Maine Republican, said in a prepared statement at the start of the Senate Special Committee on Aging’s hearing Wednesday.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.